Latent Health, a clinical AI company focused on accelerating access to life-saving medications, has raised $80 million in Series A funding. The round was co-led by Spark Capital and Transformation Capital, with participation from Conviction, McKesson Ventures, General Catalyst, and Y Combinator.
The company is addressing a major gap in healthcare delivery, where even after a diagnosis and treatment decision are made, patients often face delays or denials in receiving medication. According to the company, 42% of critical cases experience such disruptions due to complex requirements involving clinical documentation, payer rules, and pharmacy coordination.
Latent Health is building a Clinical Reasoning Engine designed to perform clinical knowledge work by analyzing patient data, interpreting drug criteria, extracting evidence, and coordinating workflows across stakeholders. By integrating electronic health records, payer guidelines, pharmacy operations, and patient engagement into a unified system, the platform replaces fragmented manual processes with AI-driven automation.
The company initially focused on prior authorization, a process known for high administrative burden and significant impact on patient outcomes. After demonstrating success in this area, Latent is expanding its platform to broader use cases where clinical knowledge must be translated into action.
Latent Health reports that more than 2 million patients are already accessing medications faster through its platform. Over the past year, the company has expanded from four to more than 45 health system partners and now works with 50% of the top 20 U.S. health systems. These include Yale New Haven Health, Ochsner Health, MetroHealth, UCI, Vanderbilt Health, Mount Sinai Health System, Henry Ford Health System, UCSF Health, and UCLA Health. The platform has reduced medication denials by more than 30% and enabled clinicians to treat twice as many patients.
Looking ahead, the company plans to extend its Clinical Reasoning Engine to proactively identify when patients should begin therapy and ensure adherence over time. The Series A funding will support expansion of its health system footprint, further development of its platform connecting hospitals, payers, pharmacies, and patients, continued investment in reliability and trust, and team growth.
Founded by Sriram Somasundaram and Rishabh Jain, Latent Health positions itself as building the intelligence infrastructure for healthcare delivery, aiming to ensure that treatment decisions translate into actual patient care.
KEY QUOTES:
“Modern medicine has advanced faster than the systems that deliver it. Today in the U.S., a patient and their doctor will sit together, look at a diagnosis, and decide on a treatment. In 42% of critical cases, that life-saving medication will be delayed or denied and may not reach the patient. This is not because the medicine doesn’t exist or the doctor made the wrong call, but because every therapy a patient receives must pass through a gauntlet of clinical documentation, payer rules, and pharmacy coordination.”
“That gauntlet is currently held together by manual labor: clinicians toggling between systems, pharmacy teams re-keying information, staff navigating phone trees to prove what a patient’s own chart already shows. The work is clinical in nature; it involves interpreting labs, applying treatment criteria, matching diagnoses to coverage rules. It is among the highest-stakes knowledge work in healthcare, and it is done almost entirely by hand.”
“For the first time, AI makes it possible to close the distance between a therapeutic decision and a patient receiving therapy.”
Latent Health, Company Statement
